Background: Scedosporium species and Lomentospora prolificans are increasing causes of invasive infections in immunocompromised hosts and many isolates are resistant to available antifungals. Our objective was to assess the in vitro potency of F901318, a member of the orotomide class of antifungals, against Scedosporium species and L. prolificans.
Introduction
Scedosporiosis is an opportunistic fungal infection that is caused by different Scedosporium species, including Scedosporium apiospermum, Scedosporium boydii, Scedosporium aurantiacum, Scedosporium dehoogii, Scedosporium minutispora and Scedosporium desertorum. 1, 2 These are ubiquitous hyaline moulds that are found in soil, polluted water, sewage and manure. 3, 4 Several species have recently been reclassified into the genus Scedosporium replacing that of Pseudallescheria (e.g. Pseudallescheria boydii, Pseudallescheria minutispora and Pseudallescheria desertorum) due to the results of phylogenetic analysis. 5 The route of infection generally involves the lungs and infections caused by these species may be difficult to delineate from pulmonary aspergillosis. 2, 6 Although these fungi can be common colonizers in patients with cystic fibrosis, invasive infections can occur, as can breakthrough infections in the persistently neutropenic and or lymphopenic, as well as lung transplant recipients. [7] [8] [9] [10] [11] In addition, pulmonary infections with dissemination to the central nervous system can occur in survivors of near-drowning events. 2, 3 Studies have reported variable antifungal activity against different species, including reduced amphotericin B and azole activity against some. 1, 12 In addition, Lomentospora prolificans, which was recently moved from the genus Scedosporium due to clear phylogenetic and morphological differences from Scedosporium species, demonstrates intrinsic resistance to all clinically available antifungal agents. 5 Thus, treatment options in patients with invasive disease due to these fungi may be limited or non-existent.
F901318 is an investigational agent that acts as an inhibitor of the pyrimidine biosynthesis enzyme dihydroorotate dehydrogenase. 13 Studies have demonstrated that this agent has potent in vitro activity against Aspergillus species, including azole-resistant isolates of A. fumigatus. [13] [14] [15] This in vitro potency has also translated into in vivo efficacy in a murine model of invasive aspergillosis. 13 Others have also reported potent in vitro activity of this 
Materials and methods

Isolates
Clinical isolates of Scedosporium species and L. prolificans from the collection of clinical isolates of the Fungus Testing Laboratory at the University of Texas Health Science Center at San Antonio were used in this study. The species identity of each isolate was determined by combined morphological/phenotypic characteristics and DNA sequence analysis of the ITS rDNA region and calmodulin gene. 16 Isolates were subcultured from frozen stocks on to potato flake agar prior to in vitro testing. 
Antifungal agents
In vitro susceptibility testing
Antifungal susceptibility testing was performed by broth microdilution testing in RPMI broth with 0.165 M MOPS (pH 7.0) according to the CLSI M38-A2 reference standard. 17 MICs were read as 100% inhibition of growth after 72 h of incubation at 35 C for F901318, amphotericin B, posaconazole and voriconazole, and the minimum effective concentration (MEC) of caspofungin was read as the lowest concentration that resulted in morphological changes (i.e. short, stubby, abnormally branched hyphae) after this same period of incubation. MICs were determined once for each antifungal against each isolate. The quality control isolate Paecilomyces variotii ATCC MYA-3630 was tested in each run and the MICs were within the acceptable range for amphotericin B, posaconazole and voriconazole for each run of the assay.
Data analysis
The MIC and MEC ranges, MIC and MEC values that inhibited 50% and 90% of the isolates (MIC/MEC 50 and MIC/MEC 90 values, respectively) and geometric mean (GM) MIC and MEC values were determined. MIC and MEC values greater than the highest concentration tested were assigned a value one dilution higher for statistical purposes. Differences in GM MICs, calculated following log 2 transformation of individual MIC values, were assessed for significance by ANOVA with Tukey's post-test for multiple comparisons. P , 0.05 was considered statistically significant. The correlation between F901318 MICs and those of the other antifungals was also assessed by Pearson correlation using log 2 -transformed MIC values.
Results
F901318 demonstrated potent in vitro activity against
Scedosporium species and L. prolificans, and this potency was maintained regardless of the species. As presented in Table 1 , the overall MIC range of F901318 for Scedosporium species was 0.008-0.5 mg/L, with MIC 50 and MIC 90 values ranging between 0.06 and 0.25 mg/L. The most potent activity of F901318 was observed against S. boydii where the GM MIC was 0.046 mg/L. Similar potency was observed against S. apiospermum where the F901318 GM MIC was 0.079 mg/L, followed by S. aurantiacum and S. dehoogii, against which the combined GM MIC was 0.193 mg/L. Against Scedosporium species, the next most potent agent was voriconazole, where the GM MICs ranged from 0.630 to 1.00 mg/L, followed closely by posaconazole with GM MICs ranging between 1.832 and 2.000 mg/L. Neither amphotericin B nor caspofungin demonstrated potent in vitro activity against the Scedosporium isolates, with GM MIC and GM MEC values ranging from 3.404 to 5.595 mg/L and 5.703 to .8 mg/L, respectively. The GM MICs of F901318 were significantly lower for all species compared with those of the comparator agents (P , 0.0001). F901318 also maintained this in vitro potency against L. prolificans with a GM MIC value of 0.168 mg/L, which was similar to the GM MIC values observed for the Scedosporium isolates. None of the other antifungals tested demonstrated in vitro activity against this species over the concentration ranges tested. Interestingly, there was a strong correlation between F901318 MICs and each of the other antifungals against S. apiospermum isolates (Pearson correlation coefficients 0.7883-0.8134; P , 0.001 for all comparisons), but not for the other species.
Discussion
F901318 is an investigational agent in a new class of antifungals, the orotomides, which prevent pyrimidine biosynthesis via inhibition of the enzyme dihydroorotate dehydrogenase. 13 Inhibition of this enzyme occurs in a fungus-specific manner, as little inhibition of recombinant human dihydroorotate dehydrogenase was observed (IC 50 .100 lM). 13 In contrast, against recombinant Aspergillus fumigatus dihydroorotate dehydrogenase, F901318 was .2200-fold more potent (IC 50 44 nM). This fungus-specific inhibition of dihydroorotate dehydrogenase results in potent antifungal activity against Aspergillus species and other clinically relevant moulds, and is maintained against azole-resistant A. fumigatus isolates. [13] [14] [15] In vivo efficacy information is available from infection models with Aspergillus species, which showed MIC values comparable to those observed here. Survival was significantly improved with F901318 compared with control in immunocompromised mice with invasive pulmonary aspergillosis due to an azole-susceptible A. fumigatus isolate and compared with both control and posaconazole in mice infected with an azole-resistant isolate harbouring the TR34/L98H mutation in CYP51A.
13
As previously noted, promising in vitro activity was already observed for F901318 in a screen against various clinically relevant moulds, including a limited number of S. apiospermum and L. prolificans isolates, although it lacks activity against Candida species. 13 The results of the current study demonstrate that this potency was maintained when the in vitro activity was tested against a larger group of Scedosporium isolates, including different species with variable susceptibility to other clinically available agents, and particularly against pan-resistant L. prolificans isolates. In contrast, variable activity was observed for amphotericin B, caspofungin, posaconazole and voriconazole, which is consistent with other in vitro studies and clinical results. 1, 4, 12 Most notably, the potency of F901318 that was observed against Scedosporium isolates was also maintained against L. prolificans, against which none of the other agents tested in this study had any appreciable in vitro activity and for which there is a clear clinical need for effective treatments. 2, 4 Current treatment strategies against invasive infections due to L. prolificans often include combination therapy, which may include the use of miltefosine, an antiparasitic agent for which there is limited clinical experience in the treatment of invasive fungal infections. 18, 19 Although the in vivo efficacy of F901318 against invasive disease caused by Scedosporium species or L. prolificans was not evaluated in this study, the results are promising, as pharmacokinetic results have demonstrated that the concentrations achieved in vivo may be well above the MICs observed in this study. In a single ascending dose study in healthy male volunteers, intravenous doses of F901318 of 0.25-4 mg/kg achieved C max concentrations ranging from 0.172 to 3.26 mg/L with half-life values of 15.2-30.2 h. 20 In addition, F901318 was well tolerated with no adverse effects reported. These results are consistent with lack of in vitro inhibition observed against recombinant human dihydroorotate dehydrogenase previously reported for F901318. 13 Thus, further studies are warranted given the promising human and animal pharmacokinetic and safety data and the in vivo efficacy that has been previously demonstrated against invasive aspergillosis. MIC values (mg/L) were measured according to CLSI M38-A2 guidelines as the lowest concentration of each agent that resulted in 100% inhibition of growth compared with the growth control.
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